On average, about 70%–100% of diagnosed pediatric CD patients given a moderate to high-dose gluten challenge will have responded by AGA-IgA, EMA-IgA, and tTG-IgA antibodies within 3 months of moderate-to-high gluten intake. The gene discussed is TGM2; the disease is Cowden disease.